...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors.
【24h】

Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors.

机译:小ber碱对多种肝毒性因子诱导的大鼠肝纤维化的保护作用和抗氧化机制。

获取原文
获取原文并翻译 | 示例

摘要

1. The aim of the present study was to investigate the effect and mechanism of berberine, an alkaloid extracted from the traditional Chinese medicine coptis, on rat liver fibrosis induced by multiple hepatotoxic factors. 2. Male Wistar rats were separated into five groups, a normal control group, a fibrotic control group and fibrotic groups treated with three different doses of berberine. The fibrotic models were established by introduction of multiple hepatotoxic factors, including CCl(4), ethanol and high cholesterol. Rats in the treatment groups were administered 50, 100 or 200 mg/kg berberine, intragastrically, daily for 4 weeks. Serum levels of alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST), hepatic activity of superoxide dismutase (SOD) and hepatic malondialdehyde (MDA) and hepatic hydroxyproline (Hyp) content were determined. Liver biopsies were obtained for histological and immunohistochemical studies to detect the expressions of alpha-smooth muscle actin (SMA) and transforming growth factor (TGF)-beta1. 3. The results showed that, compared with the fibrotic control group, serum levels of ALT and AST and hepatic content of MDA and Hyp were markedly decreased, but the activity of hepatic SOD was significantly increased in berberine-treated groups in a dose-dependent manner. In addition, histopathological changes, such as steatosis, necrosis and myofibroblast proliferation, were reduced and the expression of a-SMA and TGF-b1 was significantly downregulated in the berberine-treated groups (P < 0.01). 4. These results suggest that berberine could be used to prevent experimental liver fibrosis through regulation of the anti-oxidant system and lipid peroxidation.
机译:1.本研究的目的是研究从中药黄连中提取的生物碱小ber碱对多种肝毒性因子诱导的大鼠肝纤维化的作用及其机制。 2.将雄性Wistar大鼠分成五组,正常对照组,纤维化对照组和用三种不同剂量小碱处理的纤维化组。通过引入多种肝毒性因子(包括CCl(4),乙醇和高胆固醇)建立纤维化模型。治疗组的大鼠每天胃内给予50、100或200 mg / kg小ber碱,持续4周。测定血清丙氨酸氨基转移酶(ALT)和血清天冬氨酸氨基转移酶(AST)的水平,超氧化物歧化酶(SOD)和肝丙二醛(MDA)的肝活性以及肝羟脯氨酸(Hyp)的含量。获得肝活检标本用于组织学和免疫组化研究,以检测α-平滑肌肌动蛋白(SMA)和转化生长因子(TGF)-beta1的表达。 3.结果表明,与剂量不同的纤维化对照组相比,黄连素治疗组的血清ALT,AST,MDA和Hyp含量明显降低,但肝脏SOD活性显着升高。方式。此外,黄连素治疗组的脂肪变性,坏死和成肌纤维细胞增殖等组织病理学改变减少,α-SMA和TGF-b1的表达显着下调(P <0.01)。 4.这些结果表明,黄连素可通过调节抗氧化系统和脂质过氧化作用来预防实验性肝纤维化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号